Drug Profile
Ptilomycalin AM
Latest Information Update: 13 Jan 2003
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Substance-related disorders
Most Recent Events
- 13 Jan 2003 No development reported - Preclinical for Substance-related disorders in Japan (unspecified route)
- 24 Nov 2000 Preclinical development for Substance-related disorders in Japan (Unknown route)